Journal Article > CommentaryFull Text
Hum Vaccin Immunother. 2017 November 14; Volume 14 (Issue 2); DOI:10.1080/21645515.2017.1403705
Deen JL, Lopez AMZ, Kanungo S, Wang XY, Ahn DD, et al.
Hum Vaccin Immunother. 2017 November 14; Volume 14 (Issue 2); DOI:10.1080/21645515.2017.1403705
There are two internationally available WHO-prequalified oral rotavirus vaccines (Rotarix and RotaTeq), two rotavirus vaccines licensed in India (Rotavac and Rotasiil), one in China (Lanzhou lamb rotavirus vaccine) and one in Vietnam (Rotavin-M1), and several candidates in development. Rotavirus vaccination has been rolled out in Latin American countries and is beginning to be deployed in sub-Saharan African countries but middle- and low-income Asian countries have lagged behind in rotavirus vaccine introduction. We provide a mini-review of the leading newer-generation rotavirus vaccines and compare them with Rotarix and RotaTeq. We discuss how the development and future availability of newer-generation rotavirus vaccines that address the programmatic needs of poorer countries may help scale-up rotavirus vaccination where it is needed.